Breaks Categories: News

ThursdayOct 20, 2022 8:45 am

BioMedNewsBreaks – MetAlert Inc. (MLRT) Announces Completion of Corporate Actions, Engagement of North Equities Corp for Digital Marketing Expertise

MetAlert (OTC: MLRT), a pioneer in the field of health and safety, wearable GPS human and asset tracking systems, today announced its receipt of final approval from the regulatory bodies and completion of all corporate actions filed in the 14c on July 19. Formerly known as GTX Corp, MetAlert Inc. is now operating and trading under its new ticker symbol MLRT. In addition, as part of its marketing strategy, MetAlert retained North Equities Corp to provide digital marketing services aimed at building awareness of its rebranding and positioning in the medical device, telehealth and remote patient monitoring (“RPM”) industry. “We…

Continue Reading

WednesdayOct 19, 2022 9:30 am

BioMedNewsBreaks – MetAlert Inc. (MLRT) Featured on Stock Day Podcast

MetAlert (OTC: MLRT), a pioneer in smart, mobile and wearable tracking and recovery location-based solutions, was featured on a recent episode of the Stock Day Podcast. MetAlert’s CEO Patrick Bertagna joined Stock Day host Everett Jolly to discuss the company’s background, current projects and focus. “We have expanded the capabilities of our SmartSole(R) platform. We have added Bluetooth, WI-FI and sensors inside of the hardware platform, which will allow us to monitor not just where someone is but also how they are doing... We are also going to be adding products that monitor how people are doing at home... On…

Continue Reading

TuesdayOct 18, 2022 1:01 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Agreement with Columbia University to Extend Research Pact

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has entered into an agreement with Columbia University to extend its current research partnership efforts. The agreement outlines certain assets that are currently under development regarding the work of associate professor of clinical Neurobiology Dr. Christine Ann Denny at Columbia University Irving Medical Center. Denny and her team are studying the molecular mechanisms underlying learning and memory, including diseases such as Alzheimer’s disease. According to the announcement, Denny’s pioneering research is evaluating whether ketamine and novel inventions associated with the substance have potential…

Continue Reading

MondayOct 17, 2022 2:35 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Featured in BioWorld(TM) MedTech Article

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed an innovative platform for heart attack detection anytime, anywhere, was featured in a recent BioWorld(TM) MedTech article. “HeartBeam Inc. has been awarded a patent for what it called ‘the first and only’ 3D-vector, 12-lead ECG platform for heart attack detection, this in conjunction with a credit card-sized device inside a consumer’s wallet for personal monitoring,” the piece reads. “The company said it can record and remotely transmit a set of cardiac signals to a physician for review so that patients at high risk of cardiac arrest are not left alone…

Continue Reading

ThursdayOct 13, 2022 11:34 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Participate at Upcoming LD Micro Main Event XV Conference

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, is slated to present at this month’s LD Micro Main Event XV Conference. Scheduled for Oct. 25–27, 2022, the three-day event will be held in Los Angeles. HeartBeam CEO and founder Branislav Vajdic, PhD, will present live during the conference. His presentation will begin at 7:30 p.m. ET on Oct. 25 and can be viewed in person or online. A replay of the presentation will also be available following the event on the HeartBeam investor relations website.…

Continue Reading

WednesdayOct 12, 2022 12:18 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Publication of Innovative Mathematical Model

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced publication of a mathematical model for predicting the durability and rate of decay of neutralizing antibodies to SARS-CoV-2 in a peer-reviewed research paper in the Journal of Theoretical Biology. The publication, titled “A mathematical model of the within-host kinetics of SARS-CoV-2 neutralizing antibodies following COVID-19 vaccination,” describes a model developed with Dr. Lisette de Pillis, a professor of life sciences and mathematics at Harvey Mudd College. NAb inhibit viral binding to the human cell receptor thereby reducing…

Continue Reading

TuesdayOct 11, 2022 1:20 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints Seasoned Veteran as New Chief Medical Officer

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has named a new chief medical officer. Renowned Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will be joining the HeartBeam executive team and will support the planned advancement of the company’s product pipeline. Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School, Fitzgerald is an interventional cardiologist and has led or participated in more than 175 clinical trials and has published some 650 manuscripts/chapters. He has…

Continue Reading

TuesdayOct 11, 2022 12:53 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Formation of Subsidiary Focused on Treating Neurological Disorders

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the formation of Odyssey Neuropharma Inc. According to the update, the wholly owned subsidiary will focus on developing drugs to treat neurological disorders. The blood-brain barrier (“BBB”) represents a significant obstacle for drug delivery to the brain, and many drugs have failed in neuroscience research due to the inability to jump the hurdle that is the BBB. Odyssey will utilize its unique intranasal delivery device coupled with its powdered formulations to allow drugs to be delivered more directly to the brain, providing for quick and…

Continue Reading

TuesdayOct 11, 2022 11:25 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), The Chopra Foundation Note World Mental Health Day

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), joined partner The Chopra Foundation in recognizing World Mental Health Day, which was Monday, Oct. 11, 2022. The two organizations are working together to research the potential of psychedelic-based therapies for the treatment of mental health and to provide education about the use of psychedelics. Founded by Dr. Deepak Chopra, The Chopra Foundation is a not-for-profit organization dedicated to improving health and well-being. World Mental Health Day was designed to create an opportunity for those with mental health issues, along with advocates, governments, employers, employees and…

Continue Reading

MondayOct 10, 2022 1:36 pm

BioMedNewsBreaks – Why HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam (NASDAQ: BEAT) is a cardiac technology company whose initial focus is on providing diagnostic data through its 3D-vector 12-lead electrocardiogram (“ECG”) platform – the first and only to be developed – for heart attack detection anytime, anywhere. Its development portfolio includes HeartBeam AIMI(TM), a software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately and speedily identify a heart attack in acute care settings. Also under development is HeartBeam AIMIGo(TM), the first and only credit card-sized 12-lead output ECG device for remote heart attack detection that combines a smartphone app and cloud-based diagnostic software…

Continue Reading